Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate

Europace

Volumn 11, Issue 1, 2009, Pages 70-74

  Fragakis, Nikolaos ^a   Bikias, Athanasios ^a   Delithanasis, Ioannis ^a   Konstantinidou, Melania ^a   Liakopoulos, Nikolaos ^a   Kozirakis, Miltiadis ^a   Katsaris, George ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

Atrial fibrillation; Cardioversion; Esmolol; Ibutilide

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; ESMOLOL; IBUTILIDE; NEBIVOLOL;

ADULT; AGED; ARTICLE; CARDIOVERSION; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HEART PROARRHYTHMIA; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; SINUS BRADYCARDIA; SINUS RHYTHM;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; SULFONAMIDES; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 58149091954     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eun302     Document Type: Article

References (30)

1. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996;94:1613-21.
2. + current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992;262:99-108.
3. + current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation 1995;91:1799-806.
4. Singh BN. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol 1999;10:283-301.
5. Volgman AS, Carberry PA, Stambler B, Lewis WR, Dunn GH, Perry KT et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998;31:1414-9.
6. Newman D, Dorian P, Feder-Elituv R. Isoproterenol antagonizes drug-induced prolongation of action potential duration in humans. Can J Physiol Pharmacol 1993;71:755-60.
7. Marschang H, Brachmann J, Karolyi L, Kubler W, Schols W. Isoproterenol specifically modulates reverse rate-dependent effects of d, l-sotalol, d-sotalol, and dofetilide. J Cardiovasc Pharmacol 2000;35:443-50.
8. Kovacs A, Magyar J, Banyasz T, Nanasi PP, Szenasi G. [beta]-adrenoceptor activation plays a role in the reverse rate-dependency of effective refractory period lengthening by dofetilide in the guinea-pig atrium, in vitro. Br J Pharmacol 2003;139:1555-63.
9. Murray KT. Ibutilide. Circulation 1998;97:493-7.
10. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000;101:616-23.
11. Gray RJ, Bateman TM, Czer LS, Conklin CM, Matloff JM. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. J Am Coll Cardiol 1985;5:1451-6.
12. Naccarelli GV, Lee KS, Gibson JK, VanderLugt J. Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996;78:12-6.
13. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-90.
14. Baskin EP, Lynch JJ Jr. Differential atrial versus ventricular activities of class III potassium channel blockers. J Pharmacol Exp Ther 1998;285:135-42.
15. Duytschaever M, Blaauw Y, Allessie M. Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs. Cardiovasc Res 2005;67:69-76.
16. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-68.
17. Franz MR, Karasik PL, Li C, Moubarak J, Chavez M. Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1997;30:1785- 92.
18. Courtemanche M, Ramirez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res 1999;42:477-89.
19. Dzimiri N. Regulation of beta-adrenoceptor signaling in cardiac function and disease. Pharmacol Rev 1999;51:465-501.
20. Fragakis N, Papadopoulos N, Papanastasiou S, Kozirakis M, Maligkos G, Tsaritsaniotis E et al. Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. Pacing Clin Electrophysiol 2005;28:954-61.
21. Glatter K, Yang Y, Chatterjee K, Modin G, Cheng J, Kayser S et al. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation 2001;103:253-7.
22. Hongo RH, Themistoclakis S, Raviele A, Bonso A, Rossillo A, Glatter KA et al. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. J Am Coll Cardiol 2004;44:864-8.
23. Chiladakis JA, Kalogeropoulos A, Patsouras N, Manolis AS. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. J Am Coll Cardiol 2004;44:859-63.
24. McCray R, Ritchie DM, Roden MD, Darbar D. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. Heart rhythm 2006;3:S114-S115.
25. ShimizuW, Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 1998;98:2314- 22.
26. Karle CA, Zitron E, Zhang W, Kathofer S, Schoels W, Kiehn J. Rapid component I(Kr) of the guinea-pig cardiac delayed rectifier K(+) current is inhibited by beta(1)-adrenoreceptor activation, via cAMP/protein kinase A-dependent pathways. Cardiovasc Res 2002;53:355-62.
27. Fujiki A, Nishida K, Mizumaki K, Nagasawa H, Shimono M, Inoue H. Spontaneous onset of torsade de pointes in long-QT syndrome and the role of sympathovagal imbalance. Jpn Circ J 2001;65:1087-90.
28. Yoshiga Y, Shimizu A, Yamagata T, Hayano T, Ueyama T, Ohmura M et al. Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil. Circ J 2002;66:1024-8.
29. Steeds RP, Birchall AS, Smith M, Channer KS. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 1999;82:170-5.
30. Kanoupakis EM, Manios EG, Mavrakis HE, Tzerakis PG, Mouloudi HK, Vardas PE. Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation. Am J Cardiol 2004;94:659-62.